"A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors." by Neil Howard Segal

Selected Works of Walter J. Urba, MD, PhD

Article

A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.

Journal of Clinical Oncology (2014)

Neil Howard Segal, Memorial Sloan Kettering Cancer Center
F. Stephen Hodi, Harvard University
Rachel E. Sanborn, Providence Portland Medical Center
Thomas Gajewski, University of Chicago
Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center
Walter John Urba
Bernard A. Fox, Oregon Health & Science University
Suzanne Louise Topalian, Johns Hopkins University
Drew M. Pardoll, Johns Hopkins University School of Medicine
Georgia Kollia, Bristol-Myers Squibb
Dan McDonald, Bristol-Myers Squibb
Su Young Kim, Bristol-Myers Squibb
William Howard Sharfman, Johns Hopkins University

Link

Disciplines

Publication Date

May 20, 2014

Citation Information

Neil Howard Segal, F. Stephen Hodi, Rachel E. Sanborn, Thomas Gajewski, et al.. "A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors." Journal of Clinical Oncology Vol. 32 (2014)
Available at: http://works.bepress.com/walter-urba/134/